Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by interstitial 2 remodeling and pulmonary dysfunction. The etiology of IPF is not completely understood but 3 involves pathologic inflammation and subsequent failure to resolve fibrosis in response to 4 epithelial injury. Therapeutic strategies for IPF are limited to anti-inflammatory and 5 immunomodulatory agents, which are only partially effective. Prostaglandin E2 (PGE2) disrupts 6
Introduction 4
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible disease involving the 5 accumulation of extracellular matrix throughout alveoli and interstitial spaces, leading to the 6 destruction of lung parenchyma and impaired gas exchange 1 . Although the precise etiology of 7 IPF is unknown, the median age of onset is 66 2 , likely due to dysfunctional wound healing 3 , 8 heightened inflammation, and a reduced ability to resolve fibrosis 4 as an organism ages. Anti-9 fibrotic agents are commonly used to treat IPF but show limited efficacy, as evidenced by the 3-10 4 year estimated survival in IPF patients 2 . Therefore, novel therapeutic approaches to prevent 11 IPF pathogenesis and mitigate IPF severity are needed. 12
The initiation of IPF is often characterized by early recurrent lung epithelial injuries that 13
are not cleared and eventually lead to the deposition of fibrosis. Although anti-inflammatory 14 therapies have provided little benefit in IPF trials 5 , studies suggest that immune responses are 15 involved in disease development and progression 6 . Indeed, neutrophils accumulate in IPF 16 patient lungs [7] [8] [9] , and neutralizing neutrophil-derived products mitigates murine IPF severity 10, 11 . 17 8 To determine whether PGDHi-mediated reductions in inflammation and histopathological 1 features of fibrosis corresponded to functional improvements, we measured static lung 2 compliance (Cst) by generating pressure-volume loops in anesthetized, tracheostomized mice 3 before necropsy. PGDHi treatment attenuated the impact of bleomycin on baseline static 4 compliance, inspiratory capacity, and cellular content of the bronchoalveolar lavage fluid, as 5 compared to vehicle-treated counterparts (Fig. 4A) . Additionally, upon methacholine challenge, 6
PGDHi-treatment resulted in significantly increased forced oscillation technique measurements 7 of dynamic respiratory system compliance (Crs) and decreased respiratory system elastance 8 (Ers; Fig. 4B-C) . The bleomycin-induced loss in airway responsiveness to methacholine as 9
Newtonian airway resistance (Rn), a measure of airflow in central airways, was also significantly 10
reversed by PGDHi such that responses did not differ from naïve mice (Fig. 4D) . Lastly, the 11 rigidity of peripheral alveoli and lung parenchyma, measured as tissue elastance (H), was 12 significantly reduced with PGDHi as compared to vehicle treatment (Fig. 4E) . 13
14

Endothelial cells, mast cells, and macrophages are PGDHi targets 15
Known cellular drivers of IPF pathogenesis include alveolar epithelial cells and 16 fibroblasts 1 . To identify the cell types that PGDHi may act directly on during IPF, we dissociated 17 lung tissue from healthy mice and isolated cell populations based on surface marker expression. fractionated on the basis of CD117 to enrich mast cells, which participate in pulmonary wound 23 healing 32 , and F4/80 to enrich alveolar macrophages, which are implicated in IPF pathogenesis 24
1 . Both CD117 + and F4/80 + preparations showed striking enzyme activity enrichment relative to 25 negative counterpart cell fractions (Fig. 5A) . Additionally, 15-PGDH staining colocalized with 1 CD31, Toluidine blue, and F4/80 staining in serial sections (Fig. 5B) . These data identify 2 alveolar macrophages, mast cells, and to a lesser extent, endothelial cells, as the likely targets 3 of PGDHi therapy in murine IPF. 4
5
PGDH+ cells are present in human lung 6
Taken together, our in vivo results strongly identify 15-PGDH as a therapeutic target in 7 murine bleomycin-induced IPF. To determine if therapeutic targets exist in human lung tissue, 8
we characterized 15-PGDH expression in human lung sections incidentally removed on 9 autopsy. 15-PGDH was expressed in 6 of 6 lung specimens examined, and localized to cells 10 lining the alveoli and blood vessels (Fig. 6) , consistent with a previous report 33 . The antagonize TGFβ-mediated fibrotic signaling, we tested the capacity for 15-PGDH inhibition to 20 protect against IPF pathology in mice exposed to bleomycin. Our data show that PGDHi 21 strikingly attenuates early inflammation at day 7, which correlated with reduced weight loss and 22 mortality. We find that continuous PGDHi treatment reduces the occurrence of fibrotic lesions 23 and interstitial remodeling in the lung at day 35. Moreover, PGDHi attenuated lung dysfunction, 24 as measured by changes in compliance, resistance, and tissue rigidity. Our data identify 1 pulmonary endothelial cells, macrophages, and mast cells as the direct cellular targets of 2 PGDHi. Lastly, the presence of PGDH+ cells in human pulmonary tissue identifies 15-PGDH as 3 a potential novel therapeutic target in human IPF. 4
These data extend previous work demonstrating the capacity for PGE2 or specific 5 agonism of EP2/EP4 receptors to attenuate TGFβ-mediated pro-fibrotic signaling in pulmonary 6 fibroblasts 19,23-25 , and provide a well-tolerated and efficacious alternative to the delivery of long-7 acting prostaglandin analogs 18 . Our dual therapeutic effect on both acute inflammation and 8 chronic fibrosis, as well as, our finding that pulmonary endothelial cells, mast cells, and 9 macrophages are highly 15-PGDH active, suggest multiple discrete mechanisms contribute to 10
PGDHi-mediated protection. These results also indicate that systemic 15-PGDH inhibition may 11 exert a more potent protective effect than targeted PGE2 delivery to endothelial cells 21 and striking improvements to the dynamic compliance, resistance, and parenchymal rigidity of 21 lungs upon forced oscillation analysis. 22
During the preparation of this manuscript, corroborating data was published by 23
Bärnthaler et al. 35 . Both studies agree in the ability of PGDHi to increase local PGE2 levels, to 24 prevent the accumulation of collagen, and to improve lung function in murine IPF. Our work 25 additionally demonstrates robust PGDH enzymatic activity in pulmonary tissue as compared to 1 additional organs in which PGDHi has therapeutic efficacy 26 . Moreover, we demonstrate 2 PGDHi-mediated amelioration of acute inflammatory pathology, including local diminution of Il1b 3 and Il6, and systemic reductions in KC/GRO, and TNFα, which likely contribute to the 4 subsequent reductions in fibrosis and improvements in pulmonary function. 5
PGDHi provides a novel and well-tolerated therapeutic approach to IPF, which is 6 increasing in prevalence worldwide, particularly among aging populations. In the United States 7 prevalence is estimated at 4.0 per 100,000 persons aged 18-34, and 227.2 per 100,000 persons 8 among those >75 years 36 . A history of cigarette smoking is the strongest risk factor, with 9 additional risks including exposure to stone, wood, and organic dusts, and gastroesophageal 10 reflux, which may contribute to lung injury via microaspiration 37, 38 . While recent work has 11 yielded greater insight into the pathogenesis of IPF and related progressive fibrosis that occurs 12 in interstitial pneumonias of unknown cause, treatment options remain only partially effective. 13 FDA approved therapies include Nintedanib, an inhibitor of nonreceptor and receptor tyrosine 14 kinases, and Perfenidone a small molecule of unknown mechanism. Neither are curative but 15 demonstrate an ability to slow disease progression and can be combined with palliative care 16 approaches to improve quality of life 37, 38 . Patients deemed critical may be eligible for lung 17 transplantation, which provides a 40-50% 5-year survival rate 39 . With a clear need for improved 18 therapies for IPF and other interstitial lung diseases, our work demonstrates PGDHi holds 19 significant promise either as a standalone therapy to prevent myofibroblast differentiation and 20 reduce collagen deposition, or as a combination strategy with the currently approved therapies 21 and palliative care. 22
Of interest, this work has additional therapeutic implications for disease states also 23 characterized by fibrotic lesions. Primary myelofibrosis (PMF) is a rare bone marrow disorder 24 characterized by abnormal blood cell production which results in extensive bone marrow 12 scarring, activation of extramedullary hematopoiesis to the spleen, and a high incidence of 1 leukemic transformation 40 . Median overall survival is only six years using current standards of 2 care ruxolitinib, hydroxyurea, or bone marrow transplantation. [41] [42] [43] . PGDHi may hold significant 3 promise for PMF therapy, as inhibition of the TGFβ signaling axis has demonstrated efficacy in 4 preclinical PMF models 44, 45 . TGFβ transformation of fibroblasts plays a significant role in 5 additional fibrotic diseases including hepatic, skin, and post-radiation induced fibrosis of multiple 6 organs 46 , as well. We propose that PGDHi-mediated disruption of myofibroblast differentiation 7 will have therapeutic benefit in a number of these models and provide novel treatment strategies 8 for these poor prognosis conditions. 9
10
Methods 11
Reagents: Bleomycin sulfate was purchased from Cayman Chemical and was dissolved in 12 Cell Separation: Briefly, lungs were minced and enzymatically-digested using previously 8 described methods 47 to generate a single cell suspension. Cells were then isolated by surface 9 marker expression using Miltenyi microbead kits and LS column separation. 15-PGDH 10 enzymatic activity was measured in lysed cell fractions, or in homogenized whole organs, as 11 previously reported 26 . Activity was then normalized to input protein and were tabulated 12 graphically with error bars corresponding to standard error of the means and compared using 2 -13 tailed t-tests. 14 15 
